top of page
Portrait with Hands Clasped

Making Chronic Kidney Disease Cure a Reality

A novel conduit for regenerative kidney repair

Over 700,000 patients on dialysis alone in the US today

150,000 people requiring kidney transplant can be reduced by our therapy

Nearly 34 million people with advanced chronic kidney disease but not yet on dialysis

Product

Our Product

Our innovative approach to renal failure treatment is the use of a conduit into the kidney parenchyma to allow for steady infusion of cellular therapy (stem cells and non -stems cells) into the kidney tissue that leads to repair and regeneration of the dying kidney cells.

How It Works
Vaccine

Our Technology

Our innovative design is the creation of a biocompatible conduit implanted subcutaneously and into the kidney parenchyma to allow for steady infusion of cellular therapy (stem cells and non -stems cells) into the kidney tissue that leads to repair and regeneration of the dying kidney cells.

> Plasma rich Platelets

Sourced autologously into the kidney parenchyma to stop chronic ongoing progressive interstitial injuries in the failing kidneys. This will be helpful for patient s with active nephrotic syndrome commonly seen in DM nephropathy.

 

> Stem cells  

Mesenchymal derived pluripotent stem cells or in vivo expanded human renal epithelial cells obtained via kidney biopsy; can also be given through the conduit to regenerated new nephron cells (kidney cells) in patients with advanced chronic kidney diseases or those already with End stage kidney failure and on dialysis.

 

These two approaches of therapy can be done concurrently or in separate encounters for patients depending on their clinical kidney function status.

The eventual goal of the therapies will be to repair and regenerate kidney cells leading to improved kidney function as demonstrated by improved estimated glomerular filtration function.

Quality & Safety Assurance 

Using our approach, the risk of bleeding in the kidneys with injections of stem cells will be minimized. Our approach can lead to patients coming off dialysis even without kidney transplant.

Multiple Use Cases and Functions

Providing a conduit that allows the choice of either platelets or any cellular products including stem cells that can be tailored and given in small and spread-out doses to ensure absorption and regeneration.

Bespoke Approach to Kidney Failure

Our technology is innovative and unique in restoring lost function in the kidney by regrowing new kidney cells.  No other prior approach to kidney failure exist to restore or repair ongoing damage.

About Us

Our mission

Neukidney is a renal disease focused company that is using an innovative system for the repair of ongoing kidney damage in patients with chronic kidney disease. Our goal is to ensure a significant reduction in the number of patients ending up on dialysis.

The Company

Neukidney Inc is situated in Houston, Texas. It was created by a physician and Nephrologist with 21 years clinical experience. Our board and all co-founders are Harvard Masters graduates in Clinical operations or Harvard Business schools

About Us

Our Team

Dr. Ebima C. Okundaye is a nephrologist in Pearland, Texas and is affiliated with multiple hospitals in the Houston area. He specializes in kidney care, treating ailments such as hypertension (high blood pressure), kidney stones and kidney failure, which can now be managed without using dialysis.
ysvsj_w120h160_vH1xZSde7Kb.jpeg

Ebima Clifford Okundaye

Founder, Neukidney

A Fulbright scholar with several years’ experience leading healthcare implementation strategies for the Ministry of health, New Zealand. She migrated to the US and Harvard Master’s degree candidate for clinical operations 2023. Sophie has a strong expertise in leading new innovative projects.​
1668778086013.jfif

Sophie Oliff

Head of Design, Neukidney

Calithea is the current president and co-founder of Trialteam.org. She is a Harvard alumnus with experience successfully leading several project development strategies. She has over 20 years’ experience in leading large clinical trials and previously founded Hodges clinical group which was acquired in 2022.
1597080014925.jfif

Calethia Hodges

Advisor, Harvard University

Joseph Onyeizu is a Harvard alumni with a PHD and MBA degree. He has a Masters degree in clinical operations from Harvard university. He is an industry expert with over 10 years management experience at Merck pharmaceuticals Inc. He has managed several drug development pipelines for his organization and currently lead the global strategy division for Keytruda studies. ​
1637300912347.jfif

Joseph Onyeizu

Advisor

Shepard Bentley is a consultant with many years of experience serving as a liaison for companies seeking FDA approval processes. He currently serves as Liaison with the FDA for the company. ​
1516262259445.jfif

Shepard Bentley

Advisor

FAQs

FAQs

  • What exactly does the conduit do?
    Our goal is to regrow the dying kidneys. To achieve this, we will place a conduit in kidneys and give doses of cellular products that will mop up cytokines, repair and regrow the kidney cells leading to improve kidney function. Regrowing the kidney cells will lead to an improved kidney function and subsequent improvement in the stage of chronic kidney disease. We will result in less people needing dialysis or kidney transplantation.
  • Has the technology been tested and FDA approved?
    Our conduit is not FDA approved yet, however, here are our achieved milestones towards approval: -Successful completion of safety trial in mouse models of implanted conduit -Ongoing two months safety trial in Sheep Model – May 2023 -Accepted to the semifinalist stage of the Harvard President Innovation Award 2023
  • Who is the conduit best suited for?
    -Dialysis patients -Patients with kidney failure not yet on dialysis -Patients with failed kidney transplant Our technology can also be applied to other diseases after our unique platform and revenue sources established.
  • Where is the conduit manufactured?
    An FDA approved manufacturing facility have been already identified and verbal agreement is in place for mass market manufacturing.

Our Partners

READ MORE
bottom of page